GLAUKOS CORP.

Glaukos submitted an NDA to the FDA for Epioxa, a next-gen corneal cross-linking therapy for keratoconus, aiming to be the first non-invasive treatment without epithelium removal.

Glaukos submitted an NDA to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, aiming to reduce procedure times, improve comfort, and shorten recovery. The submission includes data from two successful Phase 3 trials.

Stuart Therapeutics appoints Tracy Valorie and Jason Werner to its Board of Directors, expanding to five members. They replace Robert O. Baratta and Diane Black, enhancing ophthalmology therapeutics expertise.

Huntsville approved Glaukos Corporation's $82M facility in Cummings Research Park, creating 154 jobs by 2030. Glaukos, a leader in ophthalmology, chose Huntsville for its skilled workforce and innovation-friendly environment. The facility's location near HudsonAlpha Institute for Biotechnology underscores Huntsville's biotech leadership.

Glaukos' Phase 3 confirmatory trial for Epioxa met primary efficacy endpoint, showing significant improvement in Kmax at 12 months, supporting NDA submission by end of 2024. Epioxa aims to be the first FDA-approved, non-invasive drug therapy for keratoconus.

Glaukos announces successful Phase 3 trial for Epioxa, meeting primary efficacy endpoint in treating keratoconus, with favorable tolerability and safety.

Glaukos Corp. plans to release Q3 2024 financial results on Nov 4, 2024, followed by a conference call and webcast at 1:30 p.m. PT. The live webcast will be available on the company’s website, with a replay archived afterward.